Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells

被引:25
作者
Boyer, MW
Waller, EK
Bray, RA
Unangst, T
Johnson, TS
Phillips, C
Jurickova, I
Winton, EF
Yeager, AM
机构
[1] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Med, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA
关键词
acute myeloid leukemia; antigen presenting cells; costimulation;
D O I
10.1038/sj.leu.2401685
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia (AML) cells are malignant counterparts of normal myeloid pathway progenitors. Myeloid progenitors differentiate into professional antigen presenting cells (APC) under the essential influence of GM-CSF along with additional cytokines. Twelve cases of human AML were tested for ability to be differentiated toward a professional APC phenotype in short-term culture with addition of GM-CSF and the following recombinant proteins: TNF alpha, IL-4, CD40 ligand, Flt3 ligand and SCF. Significant upregulation of CD80 (B7-1) and enhancement of alloantigen presentation was seen with the addition of GMCSF and TNF alpha alone or with additional cytokines. The combination of GM-CSF and TNF alpha, either alone or in combination with an additional cytokine, resulted in enhancing alloantigen presentation by at least two-fold over the media control group in 10/12 patients studied, and resulted in CD80 expression of greater than 15% in 11/12 patients studied. In AML cultures with GM-CSF and TNF alpha, coexpression of CD80 and either CD34 or an aberrant surface marker (CD56) was seen. In one case, sorted CD80(+) cells retained a characteristic cytogenetic marker and CD34 expression, proving their derivation from an AML precursor. These studies verify other reports of in vitro differentiation of human AML precursors into enhanced APC, suggesting that this phenomenon could be utilized for immunotherapy strategies aimed at enhancing presentation of leukemia antigens to T cells.
引用
收藏
页码:412 / 418
页数:7
相关论文
共 27 条
[1]   The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8(+) T-cell line with potent in vivo graft-versus-leukemia properties [J].
Boyer, MW ;
Vallera, DA ;
Taylor, PA ;
Gray, GS ;
Katsanis, E ;
Gorden, K ;
Orchard, PJ ;
Blazar, BR .
BLOOD, 1997, 89 (09) :3477-3485
[2]   ACTIVATION OF HUMAN DENDRITIC CELLS THROUGH CD40 CROSS-LINKING [J].
CAUX, C ;
MASSACRIER, C ;
VANBERVLIET, B ;
DUBOIS, B ;
VANKOOTEN, C ;
DURAND, I ;
BANCHEREAU, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1263-1272
[3]   GM-CSF AND TNF-ALPHA COOPERATE IN THE GENERATION OF DENDRITIC LANGERHANS CELLS [J].
CAUX, C ;
DEZUTTERDAMBUYANT, C ;
SCHMITT, D ;
BANCHEREAU, J .
NATURE, 1992, 360 (6401) :258-261
[4]   REPORT OF THE NATIONAL CANCER INSTITUTE-SPONSORED WORKSHOP ON DEFINITIONS OF DIAGNOSIS AND RESPONSE IN ACUTE MYELOID-LEUKEMIA [J].
CHESON, BD ;
CASSILETH, PA ;
HEAD, DR ;
SCHIFFER, CA ;
BENNETT, JM ;
BLOOMFIELD, CD ;
BRUNNING, R ;
GALE, RP ;
GREVER, MR ;
KEATING, MJ ;
SAWITSKY, A ;
STASS, S ;
WEINSTEIN, H ;
WOODS, WG .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) :813-819
[5]   Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses [J].
Choudhury, A ;
Liang, JC ;
Thomas, EK ;
Flores-Romo, L ;
Xie, QS ;
Agusala, K ;
Sutaria, S ;
Sinha, I ;
Champlin, RE ;
Claxton, DF .
BLOOD, 1999, 93 (03) :780-786
[6]   Human leukemia-derived dendritic cells: Ex-vivo development of specific antileukemic cytotoxicity [J].
Choudhury, A ;
Toubert, A ;
Sutaria, S ;
Charron, D ;
Champlin, RE ;
Claxton, DF .
CRITICAL REVIEWS IN IMMUNOLOGY, 1998, 18 (1-2) :121-131
[7]   Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia [J].
Choudhury, A ;
Gajewski, JL ;
Liang, JC ;
Popat, U ;
Claxton, DF ;
Kliche, KO ;
Andreeff, M ;
Champlin, RE .
BLOOD, 1997, 89 (04) :1133-1142
[8]  
Costello RT, 1998, EUR J IMMUNOL, V28, P90, DOI 10.1002/(SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO
[9]  
2-5
[10]  
DELAIN M, 1994, LEUKEMIA, V8, P642